Yusuke Masuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yusuke Masuda has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Noboru Taniguchi
Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
4 shared publications - Shingo Maeda
Department of Bone and Joint Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
4 shared publications - Hiroki Tawaratsumida
Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
3 shared publications - Hiroyuki Tominaga
Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
3 shared publications - Kento Shimanoe
Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
3 shared publications - Kohei Uekama
Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
3 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (4) , 100884
Inhibition of BMP–Smad1/5 signaling with DMH1 attenuates joint degeneration in a rat model of cuff tear arthropathy
- 6 October 2026
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (4) , 100884
Open AccessInhibition of BMP–Smad1/5 signaling with DMH1 attenuates joint degeneration in a rat model of cuff tear arthropathy
- Open Access
- 2 October 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 15 (10) , 1183-1195
Anti-RANKL antibody treatment mitigates subchondral bone loss and cartilage degeneration without affecting synovial inflammation in a mouse model of rotator cuff tear arthropathy
Aims: Enhanced osteoclast activity in subchondral bone is implicated in osteoarthritis (OA) progression, but the contribution of osteoclasts versus synovial inflammation in cuff tear arthropathy (CTA) remains unclear. This study investigated whether inhibition of osteoclasts using an anti-receptor activator of nuclear factor κB ligand (RANKL) antibody can suppress joint degeneration in a mouse CTA model without affecting synovial inflammation. Methods: A modified CTA (mCTA) model was established in mice by resecting the supraspinatus and infraspinatus tendons, the superior joint capsule, and the long head of the biceps tendon in the right shoulder of C57BL/6J mice. Mice were assigned to four groups: sham or mCTA, each treated with phosphate-buffered saline or anti-RANKL antibody (5 mg/kg subcutaneously every two weeks). Four weeks post-surgery, histological analyses of the humeral head were performed using the Murine Shoulder Arthritis Score (MSAS), immunohistochemistry for osteoclasts, osteoblasts, RANKL/osteoprotegerin (OPG), inflammatory cytokines, and catabolic enzymes, and quantification of synovial M1 macrophages. Subchondral bone volume (BV) was assessed via the bone volume/tissue volume ratio. Results: The mouse mCTA model reproduced clinically relevant CTA phenotypes, including cartilage degeneration, subchondral bone loss, and joint surface collapse, within four weeks. RANKL expression and osteoclast surface increased in the superior and middle zones, while osteoblasts decreased. Synovial RANKL expression was low and unchanged after mCTA surgery. Anti-RANKL antibody administration significantly suppressed osteoclast surface and preserved subchondral BV, leading to attenuation of cartilage degeneration and reduced expression of inflammatory cytokines and catabolic enzymes in cartilage and subchondral bone. The synovitis score, synovial M1 macrophages, and inflammatory factors were unaffected, indicating that suppression of osteoclasts was sufficient to mitigate joint degeneration. Conclusion: Inhibition of subchondral osteoclasts via anti-RANKL antibody reduces CTA-associated cartilage and bone degeneration without altering synovitis. These findings suggest that targeting osteoclasts may represent a promising disease-modifying strategy for CTA, and targeting RANKL with denosumab may prevent or slow shoulder OA progression. Cite this article: Bone Joint Res 2026;15(10):1183–1195.
- 2 October 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 15 (10) , 1183-1195
Open AccessAnti-RANKL antibody treatment mitigates subchondral bone loss and cartilage degeneration without affecting synovial inflammation in a mouse model of rotator cuff tear arthropathy
Aims: Enhanced osteoclast activity in subchondral bone is implicated in osteoarthritis (OA) progression, but the contribution of osteoclasts versus synovial inflammation in cuff tear arthropathy (CTA) remains unclear. This study investigated whether inhibition of osteoclasts using an anti-receptor activator of nuclear factor κB ligand (RANKL) antibody can suppress joint degeneration in a mouse CTA model without affecting synovial inflammation. Methods: A modified CTA (mCTA) model was established in mice by resecting the supraspinatus and infraspinatus tendons, the superior joint capsule, and the long head of the biceps tendon in the right shoulder of C57BL/6J mice. Mice were assigned to four groups: sham or mCTA, each treated with phosphate-buffered saline or anti-RANKL antibody (5 mg/kg subcutaneously every two weeks). Four weeks post-surgery, histological analyses of the humeral head were performed using the Murine Shoulder Arthritis Score (MSAS), immunohistochemistry for osteoclasts, osteoblasts, RANKL/osteoprotegerin (OPG), inflammatory cytokines, and catabolic enzymes, and quantification of synovial M1 macrophages. Subchondral bone volume (BV) was assessed via the bone volume/tissue volume ratio. Results: The mouse mCTA model reproduced clinically relevant CTA phenotypes, including cartilage degeneration, subchondral bone loss, and joint surface collapse, within four weeks. RANKL expression and osteoclast surface increased in the superior and middle zones, while osteoblasts decreased. Synovial RANKL expression was low and unchanged after mCTA surgery. Anti-RANKL antibody administration significantly suppressed osteoclast surface and preserved subchondral BV, leading to attenuation of cartilage degeneration and reduced expression of inflammatory cytokines and catabolic enzymes in cartilage and subchondral bone. The synovitis score, synovial M1 macrophages, and inflammatory factors were unaffected, indicating that suppression of osteoclasts was sufficient to mitigate joint degeneration. Conclusion: Inhibition of subchondral osteoclasts via anti-RANKL antibody reduces CTA-associated cartilage and bone degeneration without altering synovitis. These findings suggest that targeting osteoclasts may represent a promising disease-modifying strategy for CTA, and targeting RANKL with denosumab may prevent or slow shoulder OA progression. Cite this article: Bone Joint Res 2026;15(10):1183–1195.
- Open Access
- 4 June 2026
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 35 (12) , 2946-2960
Stepwise loss of shoulder stabilizers induces humeral head migration and progression of cuff tear arthropathy in a rat model
- 4 June 2026
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 35 (12) , 2946-2960
Open AccessStepwise loss of shoulder stabilizers induces humeral head migration and progression of cuff tear arthropathy in a rat model
- Open Access
- 15 August 2024
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (1) , 101-115
Zoledronate alleviates subchondral bone collapse and articular cartilage degeneration in a rat model of rotator cuff tear arthropathy
- 15 August 2024
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (1) , 101-115
Open AccessZoledronate alleviates subchondral bone collapse and articular cartilage degeneration in a rat model of rotator cuff tear arthropathy